Literature DB >> 24697119

Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances.

Wei Ge, De-Cai Yu, Qing-Guo Li, Xi Chen, Chen-Yu Zhang, Yi-Tao Ding.   

Abstract

BACKGROUND: Recent studies showed that serum microRNAs were aberrantly expressed in cancers, including hepatocellular carcinoma (HCC). Serum microRNA (miRNA) profiles in HCC have been filtered in our previous studies. In this research, some serum miRNAs were further validated and their clinical significances were analyzed.
METHODS: Sera from 90 HCC patients, the subjects, and 60 non-HCC normal, the controls, were used. The expression of serum microRNAs was measured using real-time reverse transcription-polymerase chain reaction. AFP, as well as other clinical materials, were summarized from the HCC databases in our hospital.
RESULTS: Serum miR-16, let-7f, and miR-21 are down-regulated in HCC while miR-98 and miR-221 are not regulated significantly. Moreover, these miRNAs are of specific clinical significance. The expression of serum miR-16 is down-regulated in the patients with a tumor more than 5 cm in diameter (p = 0.0013) and is correlated with some quantitative clinical features such as platelets (p = 0.0255), PT (p = 0.0007) and bilirubin (p = 0.0025). The expression of serum let-7f is up-regulated in the patients with a tumor more than 5 cm in diameter (p = 0.0367) and early recurrence (p = 0.0047). The expression of serum miR-21 is up-regulated in female patients with HCC (p = 0.0297).
CONCLUSIONS: Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24697119     DOI: 10.7754/clin.lab.2013.130133

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  29 in total

1.  miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature.

Authors:  Silvia Fittipaldi; Francesco Vasuri; Sonia Bonora; Alessio Degiovanni; Giacomo Santandrea; Alessandro Cucchetti; Laura Gramantieri; Luigi Bolondi; Antonia D'Errico
Journal:  Dig Dis Sci       Date:  2017-06-21       Impact factor: 3.199

Review 2.  Circulating Micro-RNAs as Diagnostic Biomarkers for Endometriosis: Privation and Promise.

Authors:  Warren B Nothnick; Ayman Al-Hendy; John R Lue
Journal:  J Minim Invasive Gynecol       Date:  2015-03-07       Impact factor: 4.137

3.  HNMDA: heterogeneous network-based miRNA-disease association prediction.

Authors:  Li-Hong Peng; Chuan-Neng Sun; Na-Na Guan; Jian-Qiang Li; Xing Chen
Journal:  Mol Genet Genomics       Date:  2018-04-23       Impact factor: 3.291

Review 4.  Serum microRNAs as potential noninvasive biomarkers for glioma.

Authors:  Xin Yu; Zheng Li
Journal:  Tumour Biol       Date:  2015-12-01

5.  Circulating miRNA-122, miRNA-199a, and miRNA-16 as Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.

Authors:  Nevine E El-Abd; Nahla A Fawzy; Suzan M El-Sheikh; Mohamed E Soliman
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

6.  Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.

Authors:  Zhengfeng Wang; Kun Zhao; Yingxuan Zhang; Xinxin Duan; Yongfu Zhao
Journal:  Pharm Res       Date:  2019-08-08       Impact factor: 4.200

7.  A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.

Authors:  Yanqiong Zhang; Xiaodong Guo; Zhiwei Li; Boan Li; Zhiyan Li; Ruisheng Li; Qiuyan Guo; Lu Xiong; Lingxiang Yu; Jingmin Zhao; Na Lin
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

8.  Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients.

Authors:  Lobna Mourad; Eman El-Ahwany; Mona Zoheiry; Hoda Abu-Taleb; Marwa Hassan; Amged Ouf; Ali Abdel Rahim; Moataz Hassanien; Suher Zada
Journal:  Cancer Biol Ther       Date:  2018-02-16       Impact factor: 4.742

9.  Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma.

Authors:  Ahmed Hassan Fawzi El-Tawdi; Marwa Matboli; Hanan Hussein Shehata; Fathy Tash; Nashwa El-Khazragy; Ahmed El-Sayed Mansour Azazy; Omar Abdel-Rahman
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

10.  Predict Colon Cancer by Pairing Plasma miRNAs: Establishment of a Normalizer-Free, Cross-Platform Model.

Authors:  Da Qin; Qingdong Guo; Rui Wei; Si Liu; Shengtao Zhu; Shutian Zhang; Li Min
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.